Yahoo · Oct 2, 2026
Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Boston Scientific (BSX) closed at $42.6, marking a -1.46% move from the previous day.
NYSE · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$42.19
Down-$0.61 (-1.45%)
Updated Oct 7, 2026, 10:19 PM
SID Score
4.8/10
Composite research score
Smart Money
63/100
Neutral
- Market cap
- 135.98B
- P/E ratio
- 48.75
- Dividend yield
- 0.00%
- 52-week range
- $41.94 – $100.90
- Volume
- 12.55M
- Avg. volume
- 9.87M
Price performance · BSX
BSX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
BSX closed at $42.19 after 21 trading sessions, down 6.20% for the selected period.
- Last close
- $42.19
- Period change
- -6.20%
- Period low
- $42.19
- Period high
- $45.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $42.47 | $42.75 | $41.995 | $42.19 | 12.55M |
| Oct 5, 2026 | $42.53 | $43.30 | $42.285 | $42.40 | 13.74M |
| Oct 2, 2026 | $43.315 | $43.44 | $41.9397 | $42.60 | 18.31M |
| Oct 1, 2026 | $43.51 | $43.96 | $42.95 | $43.23 | 17.94M |
| Sep 30, 2026 | $43.74 | $43.97 | $43.30 | $43.65 | 17.97M |
| Sep 29, 2026 | $44.145 | $44.30 | $43.22 | $43.88 | 14.61M |
| Sep 28, 2026 | $43.91 | $44.15 | $43.165 | $44.11 | 21.78M |
| Sep 25, 2026 | $44.68 | $44.84 | $43.325 | $43.92 | 15.21M |
| Sep 24, 2026 | $44.65 | $45.16 | $44.46 | $44.68 | 17.3M |
| Sep 23, 2026 | $45.00 | $45.74 | $43.985 | $44.62 | 18.57M |
| Sep 22, 2026 | $44.70 | $45.08 | $44.04 | $44.92 | 21.08M |
| Sep 21, 2026 | $42.98 | $43.81 | $42.72 | $43.72 | 25M |
| Sep 18, 2026 | $43.08 | $43.90 | $43.05 | $43.34 | 29.28M |
| Sep 17, 2026 | $43.465 | $43.66 | $42.95 | $43.55 | 32.57M |
| Sep 16, 2026 | $43.85 | $44.665 | $43.6501 | $43.91 | 28.48M |
| Sep 15, 2026 | $44.32 | $44.9889 | $43.68 | $43.87 | 16.02M |
| Sep 14, 2026 | $44.00 | $45.15 | $43.85 | $45.05 | 20.52M |
| Sep 11, 2026 | $43.19 | $43.55 | $42.795 | $42.98 | 26.99M |
| Sep 10, 2026 | $44.13 | $44.42 | $42.78 | $43.10 | 22.69M |
| Sep 9, 2026 | $45.105 | $46.265 | $44.89 | $44.96 | 17.98M |
| Sep 8, 2026 | $47.43 | $47.45 | $44.85 | $44.98 | 29.03M |
Latest BSX news
The latest Smart Investors Daily articles mentioning BSX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BSX research
Overview
Company profile and research snapshot.
Company profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | Citigroup | Neutral | — |
| Sep 24, 2026 | Wells Fargo | Equal-Weight | — |
| Sep 21, 2026 | Oppenheimer | Outperform | — |
| Sep 17, 2026 | Citigroup | Neutral | — |
| Sep 9, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 2, 2026
2 Oversold Stocks Primed to Rebound and 1 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
Yahoo · Oct 1, 2026
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t
Benzinga · Oct 1, 2026
Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029
Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale of
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
